Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CD4- and CD8-positive truncated CD19-expressing antigen presenting T cells

A preparation of ex vivo expanded, autologous CD4 and CD8 positive antigen presenting T cells (T-APCs), genetically modified with a transgene encoding a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating activity. Upon infusion, autologous CD19t-expressing T-APCs may stimulate the proliferation and activation of preadministered therapeutic CD19-targeted chimeric antigen receptor T cells (CAR-T). This may both improve the persistence of the therapeutic CAR-T cells and prevent relapse in patients with CD19 positive leukemia or lymphoma. CD19 is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD19t T-antigen presenting cells
autologous CD19t T-APC
autologous T-cell antigen presenting cells expressing CD19t
autologous T-cell antigen presenting cells expressing truncated CD19
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search